These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 28439627)

  • 1. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
    Savolainen MH; Albert K; Airavaara M; Myöhänen TT
    Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
    Li C; Biswas S; Li X; Dutta AK; Le W
    J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Parkinsonian Pathology and Neurodegeneration in Mice After Long-Term Injections of a Proteasome Inhibitor in Olfactory Bulb and Amygdala.
    Del Rey NL; Balzano T; Martin-Rodriguez L; Salinas-Rebolledo C; Trigo-Damas I; Rojas-Fernandez A; Alvarez-Erviti L; Blesa J
    Front Aging Neurosci; 2021; 13():698979. PubMed ID: 34744683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
    Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
    J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models.
    Sun F; Anantharam V; Zhang D; Latchoumycandane C; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2006 Sep; 27(5):807-15. PubMed ID: 16870259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.
    Elson JL; Kochaj R; Reynolds R; Pienaar IS
    Neurotox Res; 2018 Jul; 34(1):16-31. PubMed ID: 29218504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.
    Niu C; Mei J; Pan Q; Fu X
    Stereotact Funct Neurosurg; 2009; 87(2):69-81. PubMed ID: 19223692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
    Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
    Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson's disease.
    Pienaar IS; Harrison IF; Elson JL; Bury A; Woll P; Simon AK; Dexter DT
    Brain Struct Funct; 2015 Jan; 220(1):479-500. PubMed ID: 24292256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
    Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
    Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
    Xiao Q; Yang S; Le W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition.
    Miwa H; Kubo T; Suzuki A; Nishi K; Kondo T
    Neurosci Lett; 2005 May 20-27; 380(1-2):93-8. PubMed ID: 15854758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
    Myöhänen TT; Norrbacka S; Savolainen MH
    Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system x
    Bentea E; Van Liefferinge J; Verbruggen L; Martens K; Kobayashi S; Deneyer L; Demuyser T; Albertini G; Maes K; Sato H; Smolders I; Lewerenz J; Massie A
    Exp Neurol; 2017 Apr; 290():15-28. PubMed ID: 28024798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson's Disease in C57BL/6 Mice.
    Deng I; Corrigan F; Garg S; Zhou XF; Bobrovskaya L
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.
    Deneyer L; Albertini G; Bentea E; Massie A
    Parkinsonism Relat Disord; 2019 Nov; 68():26-32. PubMed ID: 31621614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
    Lorenc-Koci E; Lenda T; Antkiewicz-Michaluk L; Wardas J; Domin H; Smiałowska M; Konieczny J
    Neurochem Int; 2011 Jun; 58(7):839-49. PubMed ID: 21419185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
    Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
    Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.